SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Kosan BioSciences -- KOSN

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: tuck5/22/2005 4:45:19 PM
   of 933
 
[15-amidoerythromycins: new class of antibacterial macrolides]

>>J Antibiot (Tokyo). 2005 Mar;58(3):167-77.

15-amido erythromycins: synthesis and in vitro activity of a new class of macrolide antibiotics.

Shaw SJ, Abbanat D, Ashley GW, Bush K, Foleno B, Macielag M, Zhang D, Myles DC.

Kosan Biosciences, Inc., 3832, Bay Center Place, Hayward, California 94545, USA. shaw@kosan.com

An array of 15-amido substituted erythromycin A compounds was synthesized using a chemobiosynthesis approach. It was found that while the in vitro antibacterial activities of aryl amides were inferior to erythromycin A, substituted benzylamides showed equivalent and in some cases improved activity against the macrolide-resistant strains. The 15-amidoerythromycins represent a new class of antibacterial macrolides.<<

Cheers, Tuck
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext